The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Project
Research type
Research Study
Full title
The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Project
IRAS ID
227525
Contact name
Nikhil Hirani
Contact email
Sponsor organisation
Edinburgh Clinical Trials Unit
Clinicaltrials.gov Identifier
07/S1102/20, REC number of previous identical project (minus amendments herein) that was REC approved pre-IRAS
Duration of Study in the UK
14 years, 11 months, 30 days
Research summary
Idiopathic pulmonary fibrosis is a severe and progressive form of lung scarring. The average survival from the time of diagnosis is around 3 years and there current treatments have limited impact on the disease. IPF can be difficult to diagnose with certainty without a lung biopsy, which has a significant risk and complication rate. Therefore many patients have a diagnosis of possible or probable IPF which is unsatisfactory. This is part of the reason that patient with 'IPF' have differing rates of decline and these uncertainties regarding diagnosis and prognosis is hugely unsettling for both the patient and the clinician. We aim to discover simple tests that can be performed in blood and lung fluid samples that can provide the patient with more accurate information regarding the prognosis and the likely response to treatments.
REC name
East of Scotland Research Ethics Service REC 1
REC reference
17/ES/0075
Date of REC Opinion
22 Jun 2017
REC opinion
Favourable Opinion